Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions.


Stemedica has a team of experienced scientists, management and technicians to progress our proprietary technology.


Stemedica’s proprietary platform technology produces multiple progenitor cell products that meet exacting quality standards required for a cGMP licensed facility.


Stemedica is currently advancing clinical trials in the United States for several critical medical conditions.

Latest News